Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Date:9/29/2009

DETROIT, Sept. 29 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced today that it has entered into a consent decree with the U.S. Food and Drug Administration (FDA) regarding the company's drug manufacturing operations. The decree provides a series of measures that, when satisfied, will permit Caraco to resume manufacturing and distributing those products that are manufactured in its Detroit area facilities. The Company is working expeditiously to satisfy the requirements of the decree and has already retained independent cGMP experts for review of the Company's operations and to facilitate a successful result.

Under terms of the consent decree, Caraco's cessation of manufacturing operations will continue until it receives written notification from independent experts and the FDA that it is in compliance with the decree and regulations and can resume operations. Nothing in the decree prohibits Caraco from distributing FDA approved drug products that are manufactured by third parties.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's fili
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Lifesciences Corporation (NYSE: EW ), the global leader ... today reported net income for the quarter ended June 30, ... Adjusted net income on a non-GAAP basis was $124.4 ... per diluted share in the prior year period. In ... per diluted share, which included a $750 million payment ...
(Date:7/28/2015)... LA JOLLA, Calif. , July 28, 2015 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development of ... report financial results and highlights for the quarter ended ... the U.S. financial markets close. Regulus ... August 4, 2015, at 5:00 pm Eastern Daylight Time ...
(Date:7/28/2015)... -- Express Scripts Holding Company (Nasdaq: ESRX ) announced ... stockholders of $600.1 million, or $0.88 per diluted share.  ... 4, were $1.44 for the second quarter. 1  ... healthcare are validating the need for size and scale," ... what matters most is how that size and scale ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
... , , NATICK, Mass. and ... BSX ) today announced that it has received ... (FDA) and CE Mark approval to market its WallFlex® ... esophageal strictures (obstructions) caused by tumors in patients with ...
... Nov. 20 BD (Becton, Dickinson and Company) (NYSE: ... its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based ... automation platforms. , In May 2009, BD and HandyLab ... commercialize molecular assays on the HandyLab Jaguar(TM) platform, the ...
Cached Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3
(Date:7/29/2015)... , ... July 29, 2015 , ... July is National UV Awareness Month, and in ... DC shares tips on how to protect skin from the sun, as well as how ... cancer, and is one of the most common skin conditions in America. Many people do ...
(Date:7/29/2015)... ... , ... A June 10, 2015 article from the News-Press, entitled " It's ... having regular skin cancer screenings from an early age. Skin cancer can strike at ... early, skin cancer is rarely fatal; however, if left alone for too long, the ...
(Date:7/29/2015)... ... 29, 2015 , ... Employee Fiduciary, LLC announces the launch of its new, ... types of plans administered, years in business, and credentials of all Employee Fiduciary financial ... plan with Employee Fiduciary. A search can be done by zip code so a ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to ... autism, Little City took a proactive stance and began planning the Children’s Village consisting ... provides valuable support to building the third home. , “We are very pleased to ...
(Date:7/29/2015)... ... , ... Attorneys representing American families in national talcum powder lawsuits announce the ... a page dedicated to news related to pending talcum powder lawsuits, as well as ... News page was launched with eight initial articles. , “We decided to add ...
Breaking Medicine News(10 mins):Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3
... the number of influenza cases over the last four months ... statistics released by the Public// Health Agency on Dec 16. ... March or early April and the Calgary Health Region monitors ... A are; sudden headaches and fever, dry coughs and aching ...
... Ruth A. Kleinerman and his colleagues quantifies the risk ... tissue sarcomas and finds that// this risk persists for ... ,The findings published in the January 3 issue of ... importance of regular medical surveillance for these patients, the ...
... on ailments related to stomach like diarrhoea, food poisoning ... NHS Direct this festive season. NHS Direct is// a ... contacted on 0845 46 47. ,Stomach ache, ... calls received during the festive period. ,NHS ...
... U.S. Centers for Disease Control and Prevention (CDC) shows that ... ,The CDC defines binge drinking as "a common ... Alcohol Abuse and Alcoholism defines binge drinking as a pattern ... at least 0.08 percent. ,Binge drinking is now ...
... a busy man today; fielding complaints from the public, a ... taken to court, from an NGO.// ,The yoga ... hold the key to curing AIDS by performing yoga and ... earlier rubbished these statements, saying while he supported the practice ...
... A British doctor of Indian origin and his colleague are ... a challenge to the monopoly of multinational drug companies. ... and Steve Brocchini from the London School of Pharmacy are ... C. ,The two academics have devised a way ...
Cached Medicine News:Health News:Risk Of Soft Tissue Sarcomas In Hereditary Retinoblastoma Survivors 2Health News:Risk Of Soft Tissue Sarcomas In Hereditary Retinoblastoma Survivors 3Health News:NRI Doctor's R&D Model in India to Slash Cost of Drugs 2
Biosite continues its tradition of leadership and innovation with the development of the Triage TOX Drug Screen. This breakthrough technology sets new standards for clear, convenient and controlled,...
... Advanced Model 3900 Multi-Sample Osmometer is ... processing moderate to high volumes of ... of freezing-point technology for an accurate ... high, continuous throughput, the Advanced Instruments ...
... Advanced® Model 3320 Micro-Osmometer is an automated, ... sample. The Model 3320 is ideally suited ... quantity is limited.The Model 3320 employs the ... proven to be robust and dependable throughout ...
... Advanced® 2020 Multi-Sample Osmometer provides extremely ... and research settings. These results are ... method, which determines total concentration. Only ... data management, automated sample handling, and ...
Medicine Products: